Off-the-Shelf Natural Killer (NK) Cells for Oncology
Natural Killer (NK) cells are essential components of the immune system, playing an important role in the body’s defensive response against tumors and infected cells. NK cells constantly patrol the body to detect and neutralize foreign cells. Senti Bio believes there are several advantages that NK cells confer in relation to other potential immune cell types in oncology: innate killing, immune activation, previously validated efficacy and safety, and broad patient access since they may be delivered rapidly to patients in an off-the-shelf manner and in outpatient settings.
Strategic Manufacturing Capabilities Enable Production of Off-The-Shelf Cell Therapies
Through our formation of GeneFab, a contract manufacturing and synthetic biology biofoundry, Senti can control the quality and supply of our Off-the-Shelf CAR-NK cell therapies for clinical studies and ultimately commercialization. A key advantage of Off-the-Shelf cell therapies, versus autologous products that use each patient’s own cells, is the ability to manufacture large batches of drug product from healthy donor cells that can be produced in advance of clinical use, and then stored in frozen vials. Upon commercialization, if our cell therapies are approved, we expect to be able to make them broadly accessible in an off-the-shelf manner to cancer patients.